Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.

This research explored the pathogenesis of alopecia areata, finding that disrupted immune tolerance and gut microbiota are significant contributors, and highlighted the need for innovative treatments that restore immune tolerance and modulate gut microbiota to improve patient outcomes.

In this study, the researchers observed that localized vitiligo was most prevalent among patients in Saudi Arabia, commonly beginning on the face and frequently associated with thyroid disorders.

This study found that the level of expected therapeutic regrowth significantly affected hair regrowth outcomes in contact immunotherapy for alopecia areata, suggesting implications for patient education and adherence.

This review discusses the clinical features, diagnosis, and treatment of alopecia areata, while investigating potential genetic, environmental, and immunological factors involved in its etiology, but reports no new findings.

This study highlights that although mogamulizumab is highly effective for treating mycosis fungoides and Sézary syndrome, it frequently causes a variety of rashes as side effects.

This article provides a clinical update on alopecia areata, highlighting the disease's multifactorial causes, challenges it presents, and the current treatment options, with a focus on comparing international guidelines and discussing comorbidities.

This consensus statement from Saudi Arabia outlines evidence- and experience-based recommendations for diagnosing and managing alopecia areata, focusing on severity assessment, prognostic indicators, and therapeutic options, with special attention to pediatric patients and uncommon cases.

This study observed initial hair regrowth in a businessman with alopecia areata universalis treated with tofacitinib, but the effect diminished, leading to renewed hair loss.

This study suggests that congenital atrichia with papular lesions may be more common than previously thought and proposes diagnostic criteria including the observation of hypopigmented whitish streaks on the scalp.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

This case study reports that a 23-year-old woman with alopecia universalis experienced complete hair regrowth after six months of treatment with tofacitinib, a JAK-3 inhibitor.

This letter to the editor reports a case of alopecia universalis occurring alongside minimal change nephrotic syndrome, but it presents no new clinical findings.

This case report describes successful and sustained treatment of alopecia universalis with rituximab in a patient also diagnosed with dermatomyositis, suggesting a potential role for B cells in its pathogenesis.

This study describes a case of successful treatment for alopecia universalis by combining PRP therapy with eye drops, resulting in significant hair regrowth and demonstrating no systemic side effects.

In this phase I study, partial hair regrowth was observed in patients with alopecia universalis using topical JAK inhibitors, though more research is needed to confirm potential as a treatment alternative to clobetasol.

This case report describes the first known recovery from alopecia universalis using standard immunosuppression after lung transplantation in a patient with advanced bronchiectasis.

In this study, 308-nm excimer light therapy showed significant effects in some patients with treatment-resistant alopecia universalis, suggesting it as a potential alternative therapy.

In this study, researchers found that a PER3 gene SNP may be pathogenic for a new subtype of dyschromatosis universalis hereditaria, especially when combined with a SASH1 mutation.

This study found that latanoprost may be effective for treating eyelash alopecia areata, achieving cosmetically acceptable regrowth in 45% of patients.

In this 1-year study of patients with alopecia areata universalis, researchers found that 0.03% topical bimatoprost led to an acceptable cosmetic response in 43.24% of participants.

In this study, tofacitinib treatment in a male patient with alopecia areata led to significant hair regrowth and improvement in nail dystrophy symptoms, restoring finger function within 10 months.

In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

This case report describes complete hair regrowth in a patient with alopecia universalis and improved psoriasis after treatment with the oral Janus kinase inhibitor, tofacitinib.

In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

This case report documents a reversible instance of complete body hair loss (alopecia universalis) in a patient undergoing chronic hepatitis C treatment with pegylated interferon alpha-2b and ribavirin, with hair regrowth observed within three months after therapy completion.

In this study, bimatoprost solution showed better results than corticosteroid in terms of rapidity, percentage of hair regrowth, and side effects for treating scalp alopecia areata.

This review examines the outcomes of treating Brazilian patients with alopecia universalis using tofacitinib and highlights the need for randomized controlled trials to determine optimal dosing and duration.